Liposome-induced complement activation and related cardiopulmonary distress in pigs: Factors promoting reactogenicity of Doxil and AmBisome

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 2, 2012, Pages 176-184

  Szebeni, János ^a,d   Bedocs, Péter ^b,c   Rozsnyay, Zoltán ^d   Weiszhár, Zsóka ^d   Urbanics, Rudolf ^d   Rosivall, László ^e   Cohen, Rivka ^f   Garbuzenko, Olga ^f   Báthori, György ^b   Tóth, Miklós ^g   Bünger, Rolf ^c   Barenholz, Yechezkel ^f  

^a BAY ZOLTÁN NONPROFIT LTD FOR APPLIED RESEARCH   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d SeroScience Ltd   (Hungary)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^f HEBREW UNIVERSITY   (Israel)

^g UNIVERSITY OF PHYSICAL EDUCATION   (Hungary)

Author keywords

Cancer chemotherapy; Drug targeting; Immune toxicity; Infusion reactions; Nanomedicines

Indexed keywords

AMBISOME; CANCER CHEMOTHERAPY; CIS-PLATIN; CRITICAL FACTORS; DOXORUBICIN; DRUG EFFECTS; DRUG-TARGETING; HIGH RATE; HUMAN SERUM; HYPERSENSITIVITY REACTION; IMMUNE REACTION; IN-VITRO; MORPHOLOGICAL ANALYSIS; NANOMEDICINES; NEGATIVE SURFACE CHARGES; PHOSPHOLIPID BILAYER; PORCINE MODELS;

CHEMOTHERAPY; LIPOSOMES; MAMMALS; PLATINUM COMPOUNDS; SURFACE CHARGE;

PHOSPHOLIPIDS;

AMPHOTERICIN B LIPID COMPLEX; CISPLATIN; DOXORUBICIN; ENDOTOXIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C ACTIVATION RELATED PSEUDOALLERGY; CARDIOPULMONARY INSUFFICIENCY; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; TREATMENT RESPONSE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEART ARREST; HUMANS; HYPERSENSITIVITY; LIPOSOMES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES; SWINE;

SUIDAE; SUS;

EID: 84855840953     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.06.003     Document Type: Article

References (46)

1. Goyal P., Goyal K., Gurusamy S., Kumar V., Singh A., Katare Opnath Mishra D.N. Liposomal drug delivery systems-clinical applications. Acta Pharm 2005, 55:1-25.
2. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006, 1:297-315.
3. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008, 3:133-149.
4. Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 2008, 5:1003-1025.
5. Marcato P.D., Durán N. New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 2008, 8:2216-2229.
6. Gabizon A., Goren D., Cohen R., Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998, 53:275-279.
7. Amselem S., Gabizon A., Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 2006, 79:1045-1052.
8. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764-771.
9. Wingard J.R., White M.H., Anaissie E., Raffalli J., Goodman J., Arietta A., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155-1163.
10. Doxil. Package label. Available from: http://www.Doxil.com.
11. Ambisome. Package label. Available from: http://www.ambisome.com.
12. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998, 15:57-88.
13. Szebeni J., Baranyi B., Savay S., Bodo M., Morse D.S., Basta M., et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol 2000, 279:H1319-H1328.
14. Szebeni J., Baranyi B., Savay S., Lutz L.U., Jelezarova E., Bunger R. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil). J Liposome Res 2000, 10:347-361.
15. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999, 99:2302-2309.
16. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005, 216:106-121.
17. Moghimi S.M., Hamad I., Andresen T.L., Jörgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006, 20:2591-2593.
18. Priev A., Zalipsky S., Cohen R., Barenholz Y. Determination of critical micelle concentration of lipopolymers and other amphiphiles: comparison of sound velocity and fluorescent measurements. Langmuir 2002, 18:612-617.
19. Shmeeda H., Even Chen S., Honen R., Cohen R., Weintraub C., Barenholz Y. Enzymatic assays for quality control and pharmacokinetics of liposome formulations: comparison with nonenzymatic conventional methodologies. Methods Enzymol 2003, 367:272-292.
20. Zuidam N.J., Barenholz Y. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 7-heptadecyl-4-hydroxycoumarin. Biochim Biophys Acta 1997, 1329:211-222.
21. Schmidtgen M., Brandl M. Detection of lipopolysaccharides in phospholipids and liposomes using the limulus test. J Liposome Res 1995, 5:109-116.
22. Szebeni J., Muggia F.M., Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998, 90:300-306.
23. Szebeni J., Baranyi L., Savay S., Milosevits J., Bodo M., Bunger R., et al. The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol 2003, 373:136-154.
24. Bellare J.R., Davis H.T., Scriven L.E., Talmon Y. Controlled environment vitrification system: an improved sample preparation technique. J Electron Microsc Tech 1988, 10:87-111.
25. Talmon Y. Cryogenic temperature transmission electron microscopy in the study of surfactant systems. Modern characterization methods of surfactant systems 1999, 147-178. Marcel Dekker, New York. B.P. Binks (Ed.).
26. Szebeni J., Baranyi L., Sávay S., Bodó M., Milosevits J., Alving C.R., et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol 2006, 290:H1050-H1058.
27. Peleg-Shulman T., Gibson D., Cohen R., Abra R., Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta 2001, 1510:278-291.
28. R (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. Doxil clinical series 1996, Vol. 1:1-8. Gardiner-Caldwell SynerMed, Califon, New Jersey. D.S. Alberts, D.J. Garcia (Eds.).
29. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994, 33:779-786.
30. Hubert A., Lyass O., Pode D., Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000, 11:123-127.
31. Skubitz K.M., Skubitz A.P. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998, 9:45-50.
32. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
33. Alberts D.S., Garcia D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997, 54(Suppl. 4):30-45.
34. Lyass O., Hubert A., Gabizon A.A., Phase I. study of Doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 2001, 7:3040-3046.
35. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601-609.
36. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
37. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003, 14:1430-1437.
38. Szebeni J., Baranyi L., Savay S., Milosevits J., Bunger R., Laverman P., et al. Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies. J Liposome Res 2002, 12:165-172.
39. Utkhede D.R., Tilcock C.P. Studies upon the toxicity of polyethylene glycol coated lipid vesicles: acute hemodynamic effects, pyrogenicity and complement activation. J Liposome Res 1998, 8:537-550.
40. Garbuzenko O., Barenholz Y., Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 2005, 135:117-129.
41. Roeise O., Garred P., Mollnes T.E., Aasen A.O. Studies on the dose dependence of endotoxin-induced in vitro activation of the complement system. Eur Surg Res 1989, 21:34-42.
42. Szebeni J., Wassef N., Spielberg H., Rudolph A.S., Alving C.R. Complement activation by liposome-encapsulated hemoglobin in vitro. The role of endotoxin contamination. Artif Cells Blood Substit Immobil Biotechnol 1995, 23:355-363.
43. Inoue K., Takano H. Aggravating impact of nanoparticles on immune-mediated pulmonary inflammation. Sci World J 2011, 11:382-390.
44. Shin J.A., Lee E.J., Seo S.M., Kim H.S., Kang J.L., Park E.M. Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience 2010, 165:445-454.
45. Pedersen M.B., Zhou X., Larsen E.K., Sørensen U.S., Kjems J., Nygaard J.V., et al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol 2010, 184:1931-1945.
46. Szebeni J., Alving C.R., Savay S., Barenholz Y., Priev A., Danino D., et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001, 1:721-735.